辉瑞
PFE25.470USD
+0.180+0.71%
收盘 01/09, 16:00（美东）报价延迟15分钟
144.82B总市值
14.72市盈率 TTM
关于 辉瑞 公司
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
辉瑞简介
公司代码PFE
公司名称Pfizer Inc
上市日期Feb 22, 2080
CEOBourla (Albert)
员工数量81000
证券类型Ordinary Share
年结日Feb 22
公司地址66 Hudson Boulevard East
城市NEW YORK
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编10001-2192
电话12127332323
网址https://www.pfizer.com/
公司代码PFE
上市日期Feb 22, 2080
CEOBourla (Albert)
辉瑞公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+35552.00%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+12289.00%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7298.00%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-553.00%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+19457.00%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
+30962.00%
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+29174.00%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+1543.00%
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+35552.00%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+12289.00%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7298.00%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-553.00%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+19457.00%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
+30962.00%
收入明细
单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Eliquis alliance revenues and direct sales
2.02B
12.10%
Prevnar family
1.74B
10.46%
Vyndaqel family
1.59B
9.55%
Paxlovid
1.23B
7.36%
Comirnaty
1.15B
6.91%
其他
8.93B
53.62%
地区USD
名称
营收
占比
United States
10.69B
64.19%
Developed Markets
3.70B
22.19%
Emerging Markets
2.27B
13.61%
业务
地区
业务USD
名称
营收
占比
Eliquis alliance revenues and direct sales
2.02B
12.10%
Prevnar family
1.74B
10.46%
Vyndaqel family
1.59B
9.55%
Paxlovid
1.23B
7.36%
Comirnaty
1.15B
6.91%
其他
8.93B
53.62%
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.35%
State Street Investment Management (US)
5.26%
BlackRock Institutional Trust Company, N.A.
5.17%
Geode Capital Management, L.L.C.
2.27%
Norges Bank Investment Management (NBIM)
1.65%
其他
76.30%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.35%
State Street Investment Management (US)
5.26%
BlackRock Institutional Trust Company, N.A.
5.17%
Geode Capital Management, L.L.C.
2.27%
Norges Bank Investment Management (NBIM)
1.65%
其他
76.30%
股东类型
持股股东
占比
Investment Advisor
33.34%
Investment Advisor/Hedge Fund
23.13%
Research Firm
2.99%
Pension Fund
2.47%
Bank and Trust
1.76%
Sovereign Wealth Fund
1.72%
Insurance Company
1.27%
Hedge Fund
0.93%
Holding Company
0.05%
其他
32.35%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
4669
3.85B
67.65%
-88.11M
2025Q3
4830
3.80B
66.84%
-140.11M
2025Q2
4945
3.85B
67.75%
-89.09M
2025Q1
5074
3.86B
67.90%
-51.97M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
531.51M
9.35%
+833.15K
+0.16%
Sep 30, 2025
State Street Investment Management (US)
299.09M
5.26%
+2.79M
+0.94%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
294.15M
5.17%
+5.26M
+1.82%
Sep 30, 2025
Geode Capital Management, L.L.C.
129.01M
2.27%
+1.54M
+1.20%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
93.65M
1.65%
+5.87M
+6.68%
Jun 30, 2025
Wellington Management Company, LLP
60.46M
1.06%
-16.54M
-21.48%
Sep 30, 2025
State Farm Insurance Companies
57.66M
1.01%
+71.50K
+0.12%
Sep 30, 2025
MFS Investment Management
54.96M
0.97%
-17.80M
-24.46%
Sep 30, 2025
BlackRock Asset Management Ireland Limited
52.35M
0.92%
-2.30M
-4.21%
Sep 30, 2025
BlackRock Investment Management (UK) Ltd.
50.76M
0.89%
+1.88M
+3.85%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月1日 周一
更新时间: 12月1日 周一
机构名称
占比
VanEck Pharmaceutical ETF
10.43%
First Trust NASDAQ Pharmaceuticals ETF
7.73%
Franklin US Dividend Booster Index ETF
7.39%
First Trust Morningstar Dividend Leaders Index Fund
6.54%
WBI Power Factor High Dividend ETF
4.87%
Invesco Pharmaceuticals ETF
4.84%
Coastal Compass 100 ETF
4.8%
iShares U.S. Pharmaceuticals ETF
4.43%
Amplify Weight Loss Drug & Treatment ETF
4.14%
Roundhill GLP-1 & Weight Loss ETF
3.73%
查看更多
VanEck Pharmaceutical ETF
占比10.43%
First Trust NASDAQ Pharmaceuticals ETF
占比7.73%
Franklin US Dividend Booster Index ETF
占比7.39%
First Trust Morningstar Dividend Leaders Index Fund
占比6.54%
WBI Power Factor High Dividend ETF
占比4.87%
Invesco Pharmaceuticals ETF
占比4.84%
Coastal Compass 100 ETF
占比4.8%
iShares U.S. Pharmaceuticals ETF
占比4.43%
Amplify Weight Loss Drug & Treatment ETF
占比4.14%
Roundhill GLP-1 & Weight Loss ETF
占比3.73%
分红派息
近5年累计派现
36.47B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Dec 12, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 06, 2026 going ex on Jan 23, 2026
Jan 23, 2026
Mar 06, 2026
Jan 23, 2026
Oct 09, 2025
PFE.NB Final Cash Dividend of gross USD 0.43 paid on Dec 01, 2025 going ex on Nov 07, 2025
Nov 07, 2025
Dec 01, 2025
Nov 07, 2025
Jun 25, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Sep 02, 2025 going ex on Jul 25, 2025
Jul 25, 2025
Sep 02, 2025
Jul 25, 2025
Apr 23, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Jun 13, 2025 going ex on May 09, 2025
May 09, 2025
Jun 13, 2025
May 09, 2025
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
辉瑞的前五大股东是谁？
辉瑞 的前五大股东如下：
The Vanguard Group, Inc.持有股份：531.51M，占总股份比例：9.35%。
State Street Investment Management (US)持有股份：299.09M，占总股份比例：5.26%。
BlackRock Institutional Trust Company, N.A.持有股份：294.15M，占总股份比例：5.17%。
Geode Capital Management, L.L.C.持有股份：129.01M，占总股份比例：2.27%。
Norges Bank Investment Management (NBIM)持有股份：93.65M，占总股份比例：1.65%。
The Vanguard Group, Inc.持有股份：531.51M，占总股份比例：9.35%。
State Street Investment Management (US)持有股份：299.09M，占总股份比例：5.26%。
BlackRock Institutional Trust Company, N.A.持有股份：294.15M，占总股份比例：5.17%。
Geode Capital Management, L.L.C.持有股份：129.01M，占总股份比例：2.27%。
Norges Bank Investment Management (NBIM)持有股份：93.65M，占总股份比例：1.65%。
辉瑞的前三大股东类型是什么？
辉瑞 的前三大股东类型分别是：
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
有多少机构持有辉瑞(PFE)的股份？
截至2025Q4，共有4669家机构持有辉瑞的股份，合计持有的股份价值约为3.85B，占公司总股份的67.65%。与2025Q3相比，机构持股有所增加，增幅为0.81%。
哪个业务部门对辉瑞的收入贡献最大？
在FY2025Q3，Eliquis alliance revenues and direct sales业务部门对辉瑞的收入贡献最大，创收2.02B，占总收入的12.10%。
